China SXT Pharmaceuticals Inc (NASDAQ:SXTC) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 134,000 shares, a drop of 84.3% from the June 30th total of 853,600 shares. Based on an average daily trading volume, of 6,410,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.0% of the company’s shares are sold short.
Separately, ValuEngine raised China SXT Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 1st.
An institutional investor recently raised its position in China SXT Pharmaceuticals stock. UBS Group AG lifted its holdings in China SXT Pharmaceuticals Inc (NASDAQ:SXTC) by 523.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,770 shares of the company’s stock after buying an additional 104,770 shares during the period. UBS Group AG owned approximately 0.45% of China SXT Pharmaceuticals worth $66,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.20% of the company’s stock.
Shares of NASDAQ SXTC opened at $0.40 on Friday. China SXT Pharmaceuticals has a 52-week low of $0.34 and a 52-week high of $2.95. The company’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.62.
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine tablets in China. It provides oral prescription drugs and supplements under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company offers its products to pharmaceutical distributors, pharmaceutical companies, pharmacies, and hospitals through sales representatives.
Recommended Story: What are the benefits of momentum investing?
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.